BamSEC and AlphaSense Join Forces
Learn More

Syros Pharmaceuticals Inc.

NASDAQ: SYRS    
Share price (1/8/25): $0.21    
Market cap (1/8/25): $5.635 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 15 pages Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 3 pages Syros Pharmaceuticals, Inc. Amended and Restated Director Compensation Policy
12/34/56
EX-10.26
from 10-K 7 pages Confidntial October 16, 2023 Eric R. Olson, PH.D. by Electronic Mail Re: Separation Agreement 1
12/34/56
EX-10.2
from 10-Q 8 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions
12/34/56
EX-10.1
from 10-Q 15 pages Retirement and Transition Agreement
12/34/56
EX-10
from 10-K 11 pages Syros Pharmaceuticals, Inc. 2022 Inducement Stock Incentive Plan
12/34/56
EX-10.13
from 10-Q 3 pages Syros Pharmaceuticals, Inc. Amended and Restated Director Compensation Policy
12/34/56
EX-10.12
from 10-Q 5 pages Syros Pharmaceuticals, Inc. Restricted Stock Agreement
12/34/56
EX-10.11
from 10-Q 6 pages Syros Pharmaceuticals, Inc. Restricted Stock Unit Agreement
12/34/56
EX-10.10
from 10-Q 6 pages Syros Pharmaceuticals, Inc. Stock Option Agreement
12/34/56
EX-10.5
from S-4 14 pages Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan
12/34/56
EX-10.6
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.5
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 28 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 7 pages Syros Pharmaceuticals, Inc. [Form Of] Lock-Up Agreement
12/34/56
EX-10.2
from 8-K 11 pages Tyme Technologies, Inc. [Form Of] Support Agreement
12/34/56
EX-10.1
from 8-K 11 pages Syros Pharmaceuticals, Inc. [Form Of] Support Agreement
12/34/56
EX-10.1
from 10-Q 58 pages Confidential Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Master Collaboration Agreement for Companion Diagnostics
12/34/56
EX-10.12
from 10-K 5 pages Syros Pharmaceuticals, Inc. Restricted Stock Unit Agreement Granted Under 2022 Inducement Stock Incentive Plan
12/34/56
EX-10.11
from 10-K 4 pages Syros Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2022 Inducement Stock Incentive Plan
12/34/56